Literature DB >> 15335253

Pneumocystis carinii infection. Update and review.

Javed F Wazir, Naseem A Ansari.   

Abstract

OBJECTIVE: To review and update the literature on current trends with regard to Pneumocystis carinii (jiroveci ) diagnosis, treatment modalities, and its role in human disease processes. DATA SOURCES: Bibliographic databases (PubMed and Ovid) were searched for material and data between 1980 and September 2003 relevant to the review. Indexing terms used were "Pneumocystis carinii pneumonia," and "Pneumocystis jiroveci," with the English language as a constraint. Other sources were the PhD thesis of one of the authors (J.F.W., London University, 1993) and the library at the Arabian Gulf University in the Kingdom of Bahrain. STUDY SELECTION: Acquired immunodeficiency syndrome and organ transplant cases with Pneumocystis carinii pneumonia. DATA EXTRACTION: Independent extraction by 2 observers. DATA SYNTHESIS: We reviewed the major characteristics of P carinii (jiroveci ) with special emphasis on the more recently acquired data including the presence of a round pore in the cyst wall, which appears to be used for the release of sporozoites, supporting the hypothesis of sexual reproduction in P carinii (jiroveci ).
CONCLUSIONS: Opportunistic infection with P carinii (jiroveci ) remains a significant cause of morbidity and mortality in human immunodeficiency virus and non-human immunodeficiency virus-associated immunosuppressed patients. Diagnosis may be achieved in the majority of cases by routine cytochemical stains and specialized techniques such as immunocytochemistry and polymerase chain reaction. The incidence of P carinii pneumonia can significantly be reduced with effective use of prophylaxis and early detection of cases at high risk. Immunization for P carinii pneumonia is in the early stages and presents a challenging area for research.

Entities:  

Mesh:

Year:  2004        PMID: 15335253     DOI: 10.5858/2004-128-1023-PCI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  A new method for the detection of Pneumocystis jirovecii using flow cytometry.

Authors:  J Barbosa; C Bragada; S Costa-de-Oliveira; E Ricardo; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-16       Impact factor: 3.267

2.  A case report of pulmonary coinfection of Strongyloides stercoralis and Pneumocystis jiroveci.

Authors:  A J Bava; Mm Romero; R Prieto; A Troncoso
Journal:  Asian Pac J Trop Biomed       Date:  2011-08

3.  Epidemiological characteristics of pulmonary pneumocystosis and concurrent infections in pigs in Jeju Island, Korea.

Authors:  Ki-Seung Kim; Ji-Youl Jung; Jae-Hoon Kim; Sang-Chul Kang; Eui-Kyung Hwang; Bong-Kyun Park; Dae-Yong Kim; Jae-Hoon Kim
Journal:  J Vet Sci       Date:  2011-03       Impact factor: 1.672

4.  Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease.

Authors:  Soichi Itaba; Tsutomu Iwasa; Yojiro Sadamoto; Toshifumi Nasu; Tadashi Misawa; Koji Inoue; Hidehiko Shimokawa; Kazuhiko Nakamura; Ryoichi Takayanagi
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.487

5.  The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis.

Authors:  K M Williams; K W Ahn; M Chen; M D Aljurf; A L Agwu; A R Chen; T J Walsh; P Szabolcs; M J Boeckh; J J Auletta; C A Lindemans; J Zanis-Neto; M Malvezzi; J Lister; J S de Toledo Codina; K Sackey; J L H Chakrabarty; P Ljungman; J R Wingard; M D Seftel; S Seo; G A Hale; B Wirk; M S Smith; B N Savani; H M Lazarus; D I Marks; C Ustun; H Abdel-Azim; C C Dvorak; J Szer; J Storek; A Yong; M R Riches
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 6.  The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients.

Authors:  Ziyu Zhang; Qinhui Li; Xiaoyan Shen; Lankai Liao; Xia Wang; Min Song; Xi Zheng; Yulian Zhu; Yong Yang
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.